Top

Taking a novel approach to drug development

Clinical Trials

Lantern Pharma is recruiting for two Phase 2 clinical trials:
1) LP-100 for AR-targeted and Docetaxel-Pretreated mCRPC Patients 2) LP-300 for Never-Smokers with NSCLC Adenocarcinoma

See more information below.

Lantern Pharma Oncology Pipeline

Drug Name
Indication
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-100

mCRPC
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-300

NSCLC
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-184

GBM
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-184

Pediatric ATRT
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-184

Pancreatic
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-184

Bladder
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-184

Prostate
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-284

Hematologic & Solid Tumors
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-A18 (ADC Programs)

Solid Tumor
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration
Drug Name
Indication
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-100

mCRPC
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-300

NSCLC
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-184

Solid Tumors - Pancreatic
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-184

CNS Cancers - Glioblastoma
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-184

CNS Cancers - ATRT
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-184

CNS Cancers - Brain Metastases
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-184

Solid Tumors - Bladder
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-184

Prostate
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-184

CNS Cancers - Pediatric Brain Cancers
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-284

Non-Hodgkin's Lymphomas - Mantle Cell
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

ADC Program

Solid Tumors
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-100 for AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

STAGE

Phase 2

DISEASE

Metastatic Castration-Resistant Prostate Cancer

TREATMENT

Irofulven + Prednisolone 10mg

LOCATION OF TRIAL

Rigshospitalet, Dept. of Oncology
Copenhagen, Denmark, 2100

This study seeks to evaluate the anti-tumor effect after treatment of Irofulven (LP-100) in combination with prednisolone in patients who progressed on androgen receptor(AR)-targeted therapy and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer Patients. A drug response predictor (DRP®) biomarker in prostate cancer patients will identify patients likely to respond to and benefit from treatment with Irofulven.

For more information on the ongoing Phase 2 study of Irofulven in patients with mCRPC, please visit the
study page.

LP-300 for Never-smokers with NSCLC Adenocarcinoma 

STAGE

Phase 2

DISEASE

Non-Small Cell Lung Cancer

TREATMENT

LP-300 + Carboplatin and Pemetrexed

LOCATION OF TRIAL

Multiple Sites

The FDA has authorized the launch of our Phase 2 clinical trial (the “Harmonic™ Trial”) of LP-300 in combination with carboplatin and pemetrexed in never smoker patients with relapsed advanced primary adenocarcinoma of the lung after treatment with tyrosine kinase inhibitors. Our purpose in conducting the study is to determine the potential clinical advantages for this drug combination in the study-defined patient population. 

The trial is designed as a multicenter, open label, Phase 2 trial with planned enrollment of approximately 90 patients. Patients who are never smokers with lung adenocarcinoma and have relapsed after prior treatment with tyrosine kinase inhibitors will be eligible for enrollment. Following a six-patient safety lead-in stage, the trial will consist of randomization in a 2:1 allocation ratio to one of two arms: Arm A (consisting of carboplatin, pemetrexed, and LP-300) or Arm B (consisting of carboplatin and pemetrexed).

For more information on the Harmonic™ clinical trial, please visit www.harmonictrial.com or the ClinicalTrials.gov study page.

By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.